Should AIT in allergic rhinitis and/or asthma patients be interrupted to reduce visits to health care centers during the COVID-19 pandemic?
Most AIT products authorized for use in Europe indicate that AIT should be discontinued in case of infection; the same principle will apply to the COVID-19 pandemic. Patients on subcutaneous or sublingual AIT, who are diagnosed with COVID-19, those suspected of SARS-CoV-2 infection or symptomatic patients with a positive contact to SARS-CoV-2 individuals, AIT should be interrupted until the patient has recovered. In patients not infected or who have recovered from the infection, AIT could be continued (Table 3 ). These recommendations are conditional and could change as clinical data evolve.108,118